Documentos de Académico
Documentos de Profesional
Documentos de Cultura
Product Launch Risk Assessment Presentation - LATAM - February 2019 Training
Product Launch Risk Assessment Presentation - LATAM - February 2019 Training
Assessment (LTRA)
Samir Patel
LATAM
1 | TEVA | CONFIDENTIAL
Launch Technical Risk Assessments (LTRA)
1. ¿Cuál es el alcance - qué productos están
1) What is the scope – which products are cubiertos en el alcance de LTRA?
covered in the scope of LTRA? 2. ¿Qué es la Evaluación de Riesgos Técnicos
2) What is Launch Technical Risk de Lanzamiento (LTRA)?
Assessment (LTRA)? 3. ¿Por qué estamos realizando Evaluaciones
3) Why are we performing Launch Técnicas de Riesgos de Lanzamiento para
Technical Risk Assessments for these estos lanzamientos de productos?
product launches?
4. ¿Quién está llevando a cabo la LTRA?
4) Who is performing the LTRA? 5. ¿Cuándo se realiza la LTRA?
5) When are the LTRA performed? 6. ¿Cómo realizar la parte de evaluación de
6) How to perform process risk riesgos del proceso de la LTRA?
assessment portion of the LTRA? 7. ¿Cómo realizar la parte de evaluación de la
7) How to perform robustness evaluation robustez (JMP) de la LTRA?
portion (JMP) of the LTRA?
2 | TEVA | CONFIDENTIAL
Launch Technical Risk Assessments (LTRA)
1) What is the scope – which products are covered in the scope of LTRA?
• All US Launch Products that did not go through Hand-In-Hand (HiH) Process.
• Concept can be applied to any product or even investigations.
• Total US Product Launches: 347 (31 Must Win Products - ~9%)
o 2019: 117
o 2020 and Beyond: 230
3 | TEVA | CONFIDENTIAL
Launch Technical Risk Assessments (LTRA)
2) What is Launch Technical Risk Assessment (LTRA)?
2) ¿Qué es la Evaluación Técnica de Riesgos de Lanzamiento (LTRA)?
• Launch Technical Risk Assessments includes
two major steps:
• Evaluating Process Risk - using Process • La Evaluación Técnica de Riesgos de Lanzamiento incluye dos pasos principales:
Risk Assessment Tool (PRAT) or other 1. Evaluación del riesgo del proceso - utilizando la herramienta de evaluación de
appropriate methods.
• Evaluate observed process risk
riesgos del proceso (PRAT) u otros métodos apropiados.
during R&D batch executions and • Evaluar el riesgo del proceso observado durante la ejecución de lotes de
also, during pre-validation
activities – include mitigation I+D y también, durante las actividades de pre-validación - incluir planes de
plans. mitigación.
• Evaluate raw material • Evaluar las características de la materia prima para los problemas
characteristics for potential issues
and plans to control them. potenciales y los planes para controlarlos.
• Evaluate processing parameters • Evaluar los parámetros de procesamiento para los problemas potenciales y
for potential issues and control
strategy during manufacture. la estrategia de control durante la fabricación.
• Robustness Evaluation - Statistical 2. Evaluación de la robustez - Evaluación estadística de los datos durante el proceso,
evaluation of in-process, release and
stability data for R&D batches, pre- la liberación y la estabilidad de los lotes de I+D, los lotes de pre-validación, los
validation batches, validation batches lotes de validación y los lotes de pre-lanzamiento.
and pre-launch batches.
• Regression Analysis on Stability
• Análisis de regresión de los datos de estabilidad.
Data. • Herramientas de comparación estadística ANOVA (por ejemplo, Student T-
• ANOVA Statistical Comparison Test)
Tools (e.g. Tukey, Student T-Test)
• Gráficos de control y análisis de capacidad de proceso (Cpk & Cp) en datos
• Control Charts and Process
Capability Analysis (Cpk & Cp) on de lanzamiento de productos en proceso y terminados.
In-Process &
Finished Product Release Data.
4 | TEVA | CONFIDENTIAL
Launch Technical Risk Assessments (LTRA)
3) Why are we performing Launch Technical Risk Assessments?
• Three stages of product launch have been identified for the robustness evaluation portion:
Stage 2:
Refer to Slide
Process Stage 3:
Stage 1: 16 For Details
Validation / Pre-Launch
Submission on Each Stage
Qualification Batch Data is
Data is Available
Batch Data is Available
Available
Stage 2: Process Risk Stage 3: Stability Regression;
Stage 1: Process Risk (PRAT); Stability Submission vs. PV vs.
(PRAT) and Stability Regression; and Commercial Batch Comparison
Regression Submission vs. PV Batch (ANOVA); and CQA
Comparison (ANOVA) (Cpk/Control Chart) Analysis
• As a product progressives through the Stages 1, 2 & 3 additional data must be statistically
analyzed and added to the robustness evaluation (especially R&D stability data).
7 | TEVA | CONFIDENTIAL
Launch Technical Risk Assessments (LTRA)
8 | TEVA | CONFIDENTIAL
Process Risk Assessment 6) ¿Cómo realizar la parte de la evaluación de riesgos del proceso?
6) How to perform process risk 6a) El método preferido es el uso de la Herramienta de Evaluación
assessment portion of the LTRA? de Riesgos de Procesos (PRAT).
• Un archivo de Excel que resume los riesgos actuales asociados
• 6a) The preferred method is using con el producto
Process Risk Assessment Tool (PRAT) • Un riesgo observado identificado a partir del
• An excel file summarizing current risks
associated with the product seguimiento de los lotes de I+D y/o MS&T o de la
• An observed risk identified from evaluación de los registros de lotes ejecutados.
monitoring R&D and/or MS&T batches or • Materiales tamizados a través de una malla
evaluation of the executed batch records – muy fina
examples are • Mezclador sobre o bajo carga adecuada
• Screening materials through very fine screen • Tiempos de mezcla excesivos
• Blender over or under loaded • Pegado/Adherencia durante la compresión
• Excessive mixing times • Evaluar el riesgo para el proceso de fabricación y los CQA
• Sticking/Picking during compression de
• Evaluate risk to manufacturing process and • Materia prima y API: especificaciones y
CQAs from requisitos de manipulación
• Raw material and API: specifications and • Proceso de fabricación: parámetros de
handling requirements operación objetivos y rangos
• Manufacturing process: operating • Equipos de fabricación: capacidad de
parameters targets and ranges operar y mantener los parámetros de
• Manufacturing equipment: ability to operate operación y escalabilidad del proceso para
and maintain operating parameters and la producción comercial.
scalability of the process for commercial
production • Reportado como Nivel de Impacto y Nivel de
• Reported as Impact Level and Probability Probabilidad e incluye un plan de mitigación.
Level and includes mitigation plan
9 | TEVA | CONFIDENTIAL
PRAT Risk Matrix Example
10 | TEVA | CONFIDENTIAL
PRAT Risk Matrix Example
Critical
Critical
5 1, 5 5, 5 5
4 2, 4 3, 4 4 2, 4
Impact
Impact
3 3, 3 4, 3 3 1, 3 3, 3
2 1, 2 4, 2 2 1, 2 2, 2 4, 2
Insignificant
Insignificant
1 2, 1 5, 1 1 1, 1 2, 1 3, 1
0 Remote
0 Remote
0 1 2 Certain
3 4 5 6
0 1 2 Certain
3 4 5 6
Probability
Probability
11 | TEVA | CONFIDENTIAL
Process Risk Assessment 6b) Métodos alternativos para la evaluación del riesgo del
proceso de la LTRA
6b) Alternate methods for the process risk
assessment of the LTRA • Tabla que enumera los riesgos, los CQAs impactados y los
• Table listing the risks, impacted CQAs planes de mitigación con celdas resaltadas (rojo para el
and mitigation plans with highlighted riesgo alto, amarillo para el riesgo medio y verde para el
cells riesgo bajo).
(red for high risk, yellow for medium
risk and green for low risk).
• Herramienta Luz de freno - Tabla con CQAs que cruzan
• Stop Light tool – Table with CQAs and factores de riesgo como alto (celda roja), medio (celda
CMAs/CPPs cross linking risk factor as amarilla) o bajo (celda verde). Discutirá cada factor de
high (red cell), medium (yellow cell) or riesgo medio y alto bajo la tabla para detalles y plan de
low (green cell). Will discuss each mitigación.
medium and high risk factor under the
table for details and mitigation plan.
• Las herramientas alternativas mencionadas anteriormente
• The alternate tools mentioned above deben ser completadas al inicio del proceso de evaluación
should be completed at the start of the (Evaluación inicial de riesgos) y después de la ejecución del
evaluation process (Initial risk plan de mitigación (Evaluación final de riesgos).
assessment) and after mitigation plan
execution (final risk assessment). • La evaluación inicial del riesgo ayudará a identificar
• The initial risk assessment will help la planificación adecuada del ensayo.
identify appropriate trial planning. • La evaluación final del riesgo ofrecerá una visión
• The final risk assessment will give general del riesgo de la PPQ
an overview of PPQ risk.
12 | TEVA | CONFIDENTIAL
Process Risk Assessment
Risk Table
Initial Risk Assessment
Control
# Potential Risk Description Evaluations
Strategy
Although the fluid bed process is
employed to help compression flow, the
Current granulation process involves continuous LOD sampling, interruptions in the process is considered not fully
A characterization batch will be manufactured for
1 Granulation process granulation process to remove powder in filter and fluid bed walls, wide process understood/ developed. Contamination
observation and process optimization purposes
ranges and manual de-lump mechanisms. of the product and human exposures are
other concerns with this granulation.
Process run at 15 RPM. Batch record calls for 10 – 25 RPM. Currently the batch takes Speed studies were not attempted A characterization batch will be manufactured
2 Compression
numerous days to complete. during submission. where the speed studies would be attempted.
AF90T encapsulator was used for encapsulation purpose. Equipment was not set up Full fledged commercial scale studies on
A characterization batch will be manufactured for
3 Encapsulation for commercial scale. Speed studies not conducted. Partial broken tablets were seen in MG2 required to evaluate speed and
observation purposes
the capsules on inspection. other quality attributes
Stability data was over all found to be satisfactory. However, the following was noted:
225 mg , at 1 hour 60 count; 4 hour – 180 & 500 count; 12 hours – 60, 180 & 500
counts – stability regression analysis indicates that the dissolution will not meet 24 Close monitoring of the stability data at
months shelf life. the next t me point is highly advisable.
Stability trend was calculated based on three time
325 mg at 1 hour 60 count; 4 hours – 60 & 180 counts and 12 hours 180 counts – The 1 hour spec is 5-25%; 4 hour spec
4 Stability points. The 9 month stability trend will provide a
stability regression analysis indicates that the dissolution will not meet 24 months shelf is 30-60% and 12 hour specification is
better indication of actual stability trending.
life. All configuration at 12 hours tested at 6 months showed high variability. NLT 70%. The initial value of ~90% has
425 mg at 1 hour – 60, 180 counts; 4 hours – 180 & 500 counts; and 12 hours – 500 dropped to ~80% in the evaluation.
counts – stability regression analysis indicates that the dissolution will not meet 24
months shelf life.
13 | TEVA | CONFIDENTIAL
Process Risk Assessment
Stop Light Tool
14 | TEVA | CONFIDENTIAL
Launch Technical Risk Assessments (LTRA)
7) How to perform robustness evaluation 7) ¿Cómo realizar la parte de evaluación de la robustez
portion (JMP) of the LTRA? (JMP) de la LTRA?
• Stage 1: Updated Stability Regression of • Etapa 1: Regresión de estabilidad actualizada de los
the Submission Batches. lotes de Sometimiento.
• Stage 2: ANOVA Statistical Comparison • Etapa 2: Herramientas de comparación estadística
Tools (e.g. Student T-Test) the Validation
Batches and any relevant pre-validation work. ANOVA (por ejemplo, Student T-Test), los lotes de
• Stage 3: Control Charts and Cpk & Cp validación y cualquier trabajo de pre-validación
analysis of the Launch build batches. relevante.
• Etapa 3: Gráficos de control y análisis Cpk & Cp de
• Challenges los lotes de construcción de lanzamiento.
• Data must be formatted in JMP correctly.
• In many instances data is provided from • Desafíos
Word & PDF files that are scanned, • Los datos deben estar formateados
have merge cells, or data oriented in the correctamente en JMP.
wrong direction and cannot be • En muchos casos, los datos proceden de
copied/pasted easily. archivos de Word y PDF que se escanean,
• Organizing the data takes the majority of tienen celdas de fusión o datos orientados en
the time. la dirección equivocada y no pueden copiarse
o pegarse fácilmente.
• La organización de los datos toma la mayor
parte del tiempo.
15 | TEVA | CONFIDENTIAL
Data Formatting
• Typical stability report in a PDF file
with data in rows.
16 | TEVA | CONFIDENTIAL
Data Formatting
• Data needs to be organized into columns.
Model #
1 or 4
2
Specifications
3
19 | TEVA | CONFIDENTIAL
Stage 1: Updated Stability Regression of ANDA Batches
Example Lansoprazole: Low initial assay values near the specification pose a stability risk
20 | TEVA | CONFIDENTIAL
Stage 2: ANOVA Statistical Comparison of the Validation Batches
ANOVA Oneway Analysis with Tukey Comparison
• Use offers statistical tools for comparison of CQAs in order
to better understand the product. ANOVA & comparative
means (Student T Test, etc.) on a Y by X graph with non-
numeric x-axis are a visual tool for evaluating performance
between comparing strengths, types of batches, batches,
package sizes or configurations, etc.
21 | TEVA | CONFIDENTIAL
Stage 2: ANOVA Statistical Comparison of the Validation Batches
Example Lansoprazole: Blend Uniformity – High degree of variability between batches
• Averages value range from 97.5% to 107% & Individual values range from 93% to 110%
22 | TEVA | CONFIDENTIAL
Stage 2: ANOVA Statistical Comparison of the Validation Batches
Example Lansoprazole: Content Uniformity – High degree of variability between batches
• The validation batches 26Q001 (CU AV=31) failed.
23 | TEVA | CONFIDENTIAL
Stage 3: Control Charts & Cpk/Cp Analysis of Launch Build
Control Chart and Process Capability (Cpk & Cp)
• The control chart can be plotted for any number of batches; however, the Cpk & Cp values
are more relevant as you approach 20 total batches.
• Process Capability Analysis may include all batch from R&D submission to commercial
batches if no significant changes have occurred (e.g. scale-up, alternate raw material,
process changes).
• Cpk > 1.33 is in “state of control”; Cpk < 1.0 is considered “not robust”.
Process is in “State of control”. No actions required
Process is outside of
the “State of control”. Process capability, accepted based on
24 | TEVA | CONFIDENTIAL Actions needed Risk assesstment /justification
Stage 3: Control Charts & Cpk/Cp Analysis of Launch Build
Control Chart Distribution
Summary Statistics
Specifications
Process Capability
(Cpk & Cp)
25 | TEVA | CONFIDENTIAL
Stage 3: Control Charts & Cpk/Cp Analysis of Launch Build
8) ¿Cómo interpretar la producción de datos
8) How to interpret statistical data estadísticos y cuándo actuar?
output and when to act? • Problemas potenciales:
• Potential Issues: • Fallo de estabilidad previsto
• Predicted stability failure • Lotes con valores de liberación que
• Batches with release values that podrían exceder las especificaciones
could exceed specifications based basadas en la degradación o en las
on degradation or growth slopes pendientes de crecimiento.
• Comments: • Comentarios:
• Red flag not a red light – stop and • La bandera roja no es una luz roja -
think deténgase y piense
• Don’t need to mitigate every risk • No es necesario mitigar todos los riesgos
• Outcomes/Mitigation Plan: • Resultados/Plan de Mitigación:
• Monitor additional batches • Supervisar lotes adicionales
• Implement internal control limits
(ICL) • Implementar límites de control interno
(ICL)
• Root cause identification
• Identificación de la causa raíz
• Remediate product
26 | TEVA | CONFIDENTIAL • Remedio del producto
Questions?
Thank You ধন্যবাদ (Dhanyabad)
Благодаря (Blagodarya) 谢谢 (Xiè xiè)
хвала (Hvala) Děkuji
Merci Danke sehr
Efharisto Köszönöm
( תודהToda) Takk
धन्यवाद (Dhanyavaad ) Grazie
ありがとう (Arigato) Dziękuję Ci
Obrigado Mulțumesc
Spasiba Gracias
27 | TEVA | CONFIDENTIAL